EGFR tyrosine kinase inhibitor and application thereof

A technology of amino compounds, applied in the field of chemical medicine, can solve the problems of dose-dependent toxicity, no further confirmation of clinical effect, poor effect of drug-resistant T790M mutant, etc., achieve good inhibitory effect, good prognosis effect, and improve curative effect Effect

Pending Publication Date: 2021-10-12
PHARMABLOCK SCIENCES (NANJING) INC
View PDF1 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

The second-generation irreversible covalent inhibitors, such as afatinib (Afatinib), are more effective in treating EGFR (delE746-A750) and EGFR (L858R), but are not effective against drug-resistant T790M mutants. It is more active against wild-type EGFR than inhibiting EGFR (delE746-A750 / T790M) and EGFR (L858R / T790M) drug-resistant mutants, thus showing dose-dependent toxicity (Biologics, 2014, 8:183-192) , the effective treatment window cannot be obtained
Severely limit the increase of clinical dose and clinical efficacy
In addition, there are compounds CLN-081 and DZ9008 that have just entered the clinic recently. Although the in vitro activity shows that the toxicity to the wild type is reduced, their clinical effects have not been further confirmed.
In summary, compounds with higher activity and lower toxicity remain to be developed

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • EGFR tyrosine kinase inhibitor and application thereof
  • EGFR tyrosine kinase inhibitor and application thereof
  • EGFR tyrosine kinase inhibitor and application thereof

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0051] Example 1 N-(2-((2-(dimethylamino)ethyl)(methyl)amino)-5-((4-(2-phenoxyphenyl)pyrimidin-2-yl)amino ) phenyl) acrylamide

[0052]

[0053] step one:

[0054]

[0055] Compound 1.1 (1g, 6.71mmol, 1eq.), compound 1.2 (1g, 4.67mmol, 0.69eq.), tetrakistriphenylphosphine palladium (775.28mg, 670.91umol, 0.1eq.), potassium carbonate (2.78g, 20.14mmol, 3eq.) was dissolved in dioxane (20mL) and water (4mL), replaced with nitrogen three times, heated to 75°C, and reacted for 5 hours. Add EA (50mL) to the reaction solution for extraction, separate the organic phase, dry over anhydrous magnesium sulfate, spin dry, column chromatography (n-heptane: ethyl acetate = 10:1), to obtain light yellow oil (1.20g , yield: 63.23%).

[0056] Step two:

[0057]

[0058] Compound 1.3 (1.20g, 4.24mmol, 1eq.), compound 1.4 (993.92mg, 6.37mmol, 1.5eq.), cesium carbonate (4.15g, 12.73mmol, 3eq.), xphos (404.68mg, 848.88umol, 0.2 eq.), Pd 2 (dba) 3 (388.67mg, 424.44umol, 0.1eq.), diox...

Embodiment 2

[0068] Example 2 N-(2-((2-(dimethylamino)ethyl)(methyl)amino)-4-methoxy-5-((4-(2-phenoxyphenyl)pyrimidine -2-yl)amino)phenyl)acrylamide

[0069]

[0070] Using a method similar to Example 1, the compound 1.4 in Step 2 was replaced with 4-fluoro-2-methoxy-5-nitroaniline to obtain the title compound. 1 H NMR(400MHz,DMSO-d6)(ppm):9.85(brs,1H),8.90(s,1H),8.42-8.43(d,1H),8.20-8.30(m,1H),8.09(s,1H ),7.49-7.54(m,1H),7.29-7.40(m,4H),7.11-7.14(t,1H),6.98-7.02(m,4H),6.30-6.35(dd,1H),5.76-5.79 (d,1H), 3.88(s,3H), 3.0-3.29(m,2H), 2.64(m,6H). LC-MS(m / z):538.86[M+H] + .

Embodiment 3

[0071] Example 3 N-(5-((4-(2-(benzyloxy)phenyl)pyrimidin-2-yl)amino)-2-((2-(dimethylamino)ethyl)(methyl )amino)phenylamide

[0072]

[0073] Using a method similar to Example 1, the compound 1.2 in Step 1 was replaced with (2-(benzyloxy)phenyl)boronic acid to obtain the title compound. 1 H NMR(400MHz,DMSO-d6)(ppm):10.21(s,1H),9.55(s,1H),8.76(s,1H),8.42-8.43(d,1H),8.10-8.11(d,1H ),7.44-7.50(m,4H),7.33-7.44(m,4H),7.22-7.27(t,2H),7.10-7.12(t,1H),6.37-6.40(d,1H),6.31-6.32 (d,1H),5.78-5.81(dd,1H),5.26(d,2H),2.80-2.82(t,2H),2.65(s,3H),2.21-2.26(m,2H),2.20(s ,6H). LC-MS(m / z):524.09[M+H] + .

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention provides a compound as shown in formula (I), a stereoisomer or pharmaceutically acceptable salt thereof, and an application of the compound in preparation of a medicine for preventing or treating related diseases caused by EGFR mutation.

Description

technical field [0001] The invention belongs to the field of chemical medicine, and in particular relates to an EGFR tyrosine kinase inhibitor and its application. Background technique [0002] Lung cancer is one of the most common malignant tumors in the world. Lung cancer is divided into small cell lung cancer (SCLC) and non-small cell lung cancer (NSCLC). NSCLC includes squamous cell carcinoma (squamous cell carcinoma), adenocarcinoma and large cell carcinoma. Compared with SCLC, NSCLC cancer cells grow and divide more slowly, and spread and metastasize relatively later. NSCLC accounts for about 80% of all lung cancers, and the prognosis is poor, and about 75% of the patients are already in the middle and advanced stages when they are discovered. The overexpression and mutation of epidermal growth factor receptor (EGFR) has been clearly confirmed to lead to uncontrolled cell growth, which is related to the progress of most cancer diseases, especially NSCLC (Oncotarget.20...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): C07D239/42C07D401/12C07D401/04A61K31/505A61K31/506A61P35/00
CPCC07D239/42C07D401/12C07D401/04A61P35/00A61K31/505A61K31/506A61K31/167A61K31/196A61K31/404A61P3/00A61P9/00A61P29/00A61P37/02A61P37/06C07D401/14C07D403/04C07D403/14
Inventor 陈弘道胡佳琪王心悟
Owner PHARMABLOCK SCIENCES (NANJING) INC
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap